Page last updated: 2024-08-16

imatinib and azd2932

imatinib has been researched along with azd2932 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anjum, R; Barry, E; Bhavsar, D; Boyd, S; Brown, C; Campbell, A; Goldberg, K; Grondine, M; Guichard, S; Hardy, CJ; Hunt, T; Jones, RDO; Kettle, JG; Li, X; Moleva, O; Ogg, D; Overman, RC; Packer, MJ; Pearson, S; Schimpl, M; Shao, W; Smith, A; Smith, JM; Stead, D; Stokes, S; Tucker, M; Ye, Y1

Other Studies

1 other study(ies) available for imatinib and azd2932

ArticleYear
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.
    Journal of medicinal chemistry, 2018, 10-11, Volume: 61, Issue:19

    Topics: Drug Discovery; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Models, Molecular; Mutant Proteins; Mutation; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Tissue Distribution; Triazoles; Tumor Cells, Cultured

2018